|
1
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benezra R, Davis RL, Lockshon D, Turner DL
and Weintraub H: The protein Id: A negative regulator of
helix-loop-helix DNA binding proteins. Cell. 61:49–59. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Finkel T, Duc J, Fearon ER, Dang CV and
Tomaselli GF: Detection and modulation in vivo of helix-loop-helix
protein-protein interactions. J Biol Chem. 268:5–8. 1993.PubMed/NCBI
|
|
4
|
Lasorella A, Uo T and Iavarone A: Id
proteins at the cross-road of development and cancer. Oncogene.
20:8326–8333. 2001. View Article : Google Scholar
|
|
5
|
Ruzinova MB and Benezra R: Id proteins in
development, cell cycle and cancer. Trends Cell Biol. 13:410–418.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rotzer D, Krampert M, Sulyok S, Braun S,
Stark HJ, Boukamp P and Werner S: Id proteins: Novel targets of
activin action, which regulate epidermal homeostasis. Oncogene.
25:2070–2081. 2006. View Article : Google Scholar
|
|
7
|
Li XJ, Hata K and Mizuguchi J: Engagement
of membrane immunoglobulin enhances Id3 promoter activity in
WEHI-231 B lymphoma cells. Acta Pharmacol Sin. 26:486–491. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee KT, Lee YW, Lee JK, Choi SH, Rhee JC,
Paik SS and Kong G: Overexpression of Id-1 is significantly
associated with tumour angiogenesis in human pancreas cancers. Br J
Cancer. 90:1198–1203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng Y, Kang Q, Luo Q, Jiang W, Si W, Liu
BA, Luu HH, Park JK, Li X, Luo J, et al: Inhibitor of DNA
binding/differentiation helix-loop-helix proteins mediate bone
morphogenetic protein-induced osteoblast differentiation of
mesenchymal stem cells. J Biol Chem. 279:32941–32949. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kee BL, Rivera RR and Murre C: Id3
inhibits B lymphocyte progenitor growth and survival in response to
TGF-beta. Nat Immunol. 2:242–247. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Simbulan-Rosenthal CM, Daher A, Trabosh V,
Chen WC, Gerstel D, Soeda E and Rosenthal DS: Id3 induces a
caspase-3- and -9-dependent apoptosis and mediates UVB
sensitization of HPV16 E6/7 immortalized human keratinocytes.
Oncogene. 25:3649–3660. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koyama T, Suzuki H, Imakiire A, Yanase N,
Hata K and Mizuguchi J: Id3-mediated enhancement of
cisplatin-induced apoptosis in a sarcoma cell line MG-63.
Anticancer Res. 24:1519–1524. 2004.PubMed/NCBI
|
|
13
|
Li XJ, Zhu CD, Yu W, Wang P, Chen FF, Xia
XY and Luo B: Overexpression of Id3 induces apoptosis of A549 human
lung adenocarcinoma cells. Cell Prolif. 45:1–8. 2012. View Article : Google Scholar
|
|
14
|
Chen FF, Liu Y, Wang F, et al: Effects of
upregulation of Id3 in human lung adenocarcinoma cells on
proliferation, apoptosis, mobility and tumorigenicity. Cancer Gene
Therapy. 22:431–437. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fridman E, Skarda J, Pinthus JH, Ramon J
and Mor Y: Expression of multidrug resistance-related protein
(MRP-1), lung resistance-related protein (LRP) and topoisomerase-II
(TOPO-II) in Wilms' tumor: Immunohistochemical study using TMA
methodology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
152:47–51. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Asnaghi L, Calastretti A, Bevilacqua A,
D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S and Nicolin A:
Bcl-2 phosphorylation and apoptosis activated by damaged
microtubules require mTOR and are regulated by Akt. Oncogene.
23:5781–5791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scagliotti GV, Novello S and Selvaggi G:
Multidrug resistance in non-small-cell lung cancer. Ann Oncol.
10(Suppl 5): S83–S86. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Damdinsuren B, Nagano H, Kondo M, Yamamoto
H, Hiraoka N, Yamamoto T, Marubashi S, Miyamoto A, Umeshita K, Dono
K, et al: Expression of Id proteins in human hepatocellular
carcinoma: Relevance to tumor dedifferentiation. Int J Oncol.
26:319–321. 2005.PubMed/NCBI
|
|
20
|
Asirvatham AJ, Carey JP and Chaudhary J:
ID1-, ID2- and ID3-regulated gene expression in E2A positive or
negative prostate cancer cells. Prostate. 67:1411–1420. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arnold JM, Mok SC, Purdie D and
Chenevix-Trench G: Decreased expression of the Id3 gene at 1p36.1
in ovarian adenocarcinomas. Br J Cancer. 84:352–359. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moon C, Oh Y and Roth JA: Current status
of gene therapy for lung cancer and head and neck cancer. Clin
Cancer Res. 9:5055–5067. 2003.PubMed/NCBI
|
|
23
|
Wilson JW, Deed RW, Inoue T, Balzi M,
Becciolini A, Faraoni P, Potten CS and Norton JD: Expression of Id
helix-loop-helix proteins in colorectal adenocarcinoma correlates
with p53 expression and mitotic index. Cancer Res. 61:8803–8810.
2001.PubMed/NCBI
|
|
24
|
Rockman SP, Currie SA, Ciavarella M,
Vincan E, Dow C, Thomas RJ and Phillips WA: Id2 is a target of the
beta-catenin/T cell factor pathway in colon carcinoma. J Biol Chem.
276:45113–45119. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee SH, Hao E, Kiselyuk A, Shapiro J,
Shields DJ, Lowy A, Levine F and Itkin-Ansari P: The Id3/E47 axis
mediates cell-cycle control in human pancreatic ducts and
adenocarcinoma. Mol Cancer Res. 9:782–790. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kamalian L, Forootan SS, Bao ZZ, Zhang Y,
Gosney JR, Foster CS and Ke Y: Inhibition of tumourigenicity of
small cell lung cancer cells by suppressing Id3 expression. Int J
Oncol. 37:595–603. 2010.PubMed/NCBI
|
|
27
|
Pucci B, Kasten M and Giordano A: Cell
cycle and apoptosis. Neoplasia. 2:291–299. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu MD, Xu JC, Fan Y, Xie QC, Li Q, Zhou
CX, Mao M and Yang Y: Hypoxia-inducible factor 1 promoter-induced
JAB1 overexpression enhances chemotherapeutic sensitivity of lung
cancer cell line A549 in an anoxic environment. Asian Pac J Cancer
Prev. 13:2115–2120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu
SJ, Li WD and Chen W: FBW7 upregulation enhances cisplatin
cytotoxicity in non-small cell lung cancer cells. Asian Pac J
Cancer Prev. 14:6321–6326. 2013. View Article : Google Scholar
|
|
30
|
Langenfeld E, Deen M, Zachariah E and
Langenfeld J: Small molecule antagonist of the bone morphogenetic
protein type I receptors suppresses growth and expression of Id1
and Id3 in lung cancer cells expressing Oct4 or nestin. Mol Cancer.
12:1292013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Langenfeld E, Hong CC, Lanke G and
Langenfeld J: Bone morphogenetic protein type I receptor
antagonists decrease growth and induce cell death of lung cancer
cell lines. PLoS One. 8:e612562013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen D, Forootan SS, Gosney JR, Forootan
FS and Ke Y: Increased expression of Id1 and Id3 promotes
tumorigenicity by enhancing angiogenesis and suppressing apoptosis
in small cell lung cancer. Genes Cancer. 5:212–225. 2014.PubMed/NCBI
|
|
33
|
Castañon E, Bosch-Barrera J, López I,
Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A
and Gil-Bazo I: Id1 and Id3 co-expression correlates with clinical
outcome in stage III-N2 non-small cell lung cancer patients treated
with definitive chemoradiotherapy. J Transl Med. 11:132013.
View Article : Google Scholar : PubMed/NCBI
|
